Laurus Labs Faces 8% Stock Plunge as Analysts Predict Bleak Future

Pharmaceutical company, Laurus Labs witnessed a sharp decline in its shares, plunging by over 8% on Monday, October 23. This downturn came in response to analysts' projections of a potentially severe 35% downside in the stock over the next 12 months. The company reported disappointing quarterly figures for the period spanning July to September.

Kotak Institutional Equities, a well-known brokerage firm, took a bearish stance on Laurus Labs, assigning the stock a 'Sell' rating with a target price of Rs 270 per share. This projection indicates a substantial 32% decline from the closing price on the previous Friday.

Laurus Labs shares began their downward trajectory, slipping by more than 8% to hit a low of ₹366.45 during morning trading on the National Stock Exchange (NSE).

Kotak Institutional Equities expressed concern over the company's underwhelming performance in the September quarter, describing it as 'insipid'. Laurus Labs missed expectations across various segments in the second quarter of fiscal year 2024, with a notable shortfall in the supply of animal healthcare contracts. The brokerage firm also voiced apprehension about the absence of any visible commercial Contract Development and Manufacturing Organization (CDMO) contracts, emphasizing that the persistent weakness in the core business over the past two years is indeed unsettling.

The brokerage added, 'There still remains a downside risk to our lowered assumption of Rs 1,920 crore Synthesis sales in FY25.'

Laurus Labs recently reported a significant 23% year-on-year drop in revenue, bringing it down to Rs 2,406 crore for the September quarter. The operating profit also took a hit, plummeting by 61% year-on-year to Rs 356 crore in the same period.

As of 11:45 am, Laurus Labs shares were trading at ₹367.30 on NSE, representing a further 8.30% decline. The future of the company remains uncertain, with investors closely monitoring the situation in light of these concerning developments.